YourStory Media’s Post

Healthtech startup ErlySign has secured INR 16 Cr (around $1.8 Mn) in Pre-Series A funding round from Ashish Kacholia to further develop its cancer diagnostic solutions👇 The fresh proceeds will be deployed in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market, the startup said in its statement. “It will support research and development, team expansion, and further patent filings,” it added. Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign or CURO Biosciences develops solutions for early detection of oral cancer. The company also claims to offer India’s first salivary biomarker based test which can identify pre- cancerous conditions much before visible symptoms emerge. To read the in-depth article, click here: https://4-2.co/3PARWVH #news #startup #funding

ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia: Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia.  The proceeds will be used in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market.  Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign develops solutions for early detection of oral cancer.  The startup also claims to offer India’s first salivary biomarker-based test which can identify pre-cancerous conditions much before visible symptoms emerge.  Looking ahead, ErlySign plans to use CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes.  #Healthtech #Startup #Investment

ExSURE PVT. LTD., an innovative biotech startup revolutionizing cancer treatment, has successfully raised Rs 3 crore in a seed funding round led by Unicorn India Ventures! Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is focused on reducing the side effects and toxicity of anti-cancer drugs using a cutting-edge exosome-based drug delivery platform. This technology targets both cancer and cancer stem cells, aiming to improve the quality of life for patients and minimize chemotherapy’s toxic effects. The fresh funds will help Exsure complete its non-clinical studies, expand its global reach, and support the promotion of key products like Exosure, Leucosure, PlantExosure, and Dr. Berries. With fivefold growth in the past fiscal year, Exsure is on track to service 50+ clients this year and has been selected for the OIST Innovation Accelerator Program in Japan! The Indian biotech sector is on track to reach $150 billion by 2025, and Exsure is well-positioned to be a major player in this booming industry. Read More: https://lnkd.in/gCXU69hq #Exsure #SeedFunding #Biotech #CancerTreatment #ExosomeTechnology #Innovation #HealthTech #Startups #Biotechnology #CancerResearch #R&D #GlobalExpansion #OISTInnovationAccelerator #UnicornIndiaVentures

Alphan Manas Manas AI 🤖 sana çok yakışır 😉 Reid Hoffman’s Manas AI raises $24.6M, a fraction of other AI drug discovery startups LinkedIn founder Reid Hoffman and Siddhartha Mukherjee researcher and author of the book “The Emperor of All Maladies,” have co-founded an AI-powered drug discovery startup, Manas AI. The company, which will initially focus on breast cancer, prostate cancer, and lymphoma, has raised $24.6 million in seed funding from Hoffman, General Catalyst, and Greylock.

Biotech startup ExSURE PVT. LTD. raises Rs 3-Cr in seed round Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure focuses on reducing anti-cancer drug’s side effects and toxicity using its patented exosomal drug delivery platform. This platform targets both cancer and cancer stem cells, aiming to minimize chemotherapy’s toxic effects and reduce the likelihood of cancer relapse, ultimately improving the quality of life for cancer patients. #BiotechIndia #CancerTreatment #StartupFunding #Biotech #stemcells

This Startup's Breakthrough Could Change Cancer Treatment Forever! 🅰🅳 𝘉𝘳𝘪𝘯𝘨 𝘺𝘰𝘶𝘳 𝘚𝘵𝘢𝘳𝘵𝘶𝘱 𝘐𝘥𝘦𝘢 𝘵𝘰 𝘌𝘹𝘦𝘤𝘶𝘵𝘪𝘰𝘯, 𝘉𝘰𝘰𝘬 𝘍𝘙𝘌𝘌 𝘚𝘭𝘰𝘵: https://lnkd.in/gxv86m5J Bhubaneswar-based biotech startup Exsure has successfully raised ₹3 crore in a seed funding round led by Unicorn India Ventures. Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is pioneering a patented exosomal drug-delivery platform aimed at reducing the side effects and toxicity of anti-cancer drugs. This innovative approach targets both cancer and cancer stem cells, potentially decreasing chemotherapy's harmful effects and reducing the likelihood of cancer relapse. The newly acquired funds will be utilized to advance non-clinical studies of their exosome-based drug delivery vehicle and to expand their range of in-house manufactured R&D products, including Exosure, Leucosure, PlantExosure, and Dr. Berries. #BiotechInnovation #CancerResearch #StartupFunding #HealthcareRevolution

Meet IntraGel Therapeutics, an Asper Prize 2024 Finalist! What is their #StartupStory? Intragel, founded in 2021 by CEO Peter Siman after his mother’s death from untreatable lung cancer, addresses the needs of 8 million inoperable cancer patients. About 40% of these patients, like Peter’s mother, cannot undergo chemotherapy due to toxicity concerns. Intragel’s innovation, SRGel, is a patent-protected gel-like polymer capable of incorporating up to 50% drug payload. Applied directly into tumors, SRGel releases the drug over several weeks, replacing multiple chemotherapy courses, enhancing intratumoral drug concentration and efficacy with minimal systemic toxicity, hitting the jackpot of interventional oncology space. This breakthrough technology showed promise in Phase 1 clinical trials for chemo- and radio-resistant Head and Neck cancer.  Intragel is currently raising $10 million to finalize Phase I trials, build a GMP production facility, execute Phase II trials, and fund marketing efforts. Follow along to see if they will be the rising Startup of the year! The Hebrew University of Jerusalem, Asper Foundation, Yissum, The Hebrew University Tech Transfer Company, Amnon Dekel, PhD, Peter Siman Bridges Israel, Deep Insight, Grove Ventures, JVP, Meron Capital, OurCrowd, PICO Venture Partners , Target Global, 10D #technology #startup #innovation #asperprize 

Seattle Immunotherapy Startup Umoja Biopharma Raises $100M https://lnkd.in/gqJC7qFg Another Seattle-area health startup is raising a big new round of funding. Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. Umoja is developing a multi-pronged technology that retools a patient’s immune system in vivo, or within a living organism, to generate cancer-fighting cells inside the body. The company launched in 2019 and is working to commercialize technology developed at Seattle Children’s Research Institute and Purdue University. Its headquarters are in Seattle, and it has a manufacturing operations site in Colorado. The post Seattle Immunotherapy Startup Umoja Biopharma Raises $100M appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

BioSapien, a USA- and UAE-based biotech startup, has secured $5.5 million in a pre-Series A funding round led by Global Ventures, with participation from Dara Holdings. The funds will be used to accelerate the development of MediChip, a 3D-printed implant designed to transform cancer treatment by delivering drugs directly to tumors. Noor Sweid of Global Ventures and Khatija A., CEO of BioSapien, highlight the innovative potential of this breakthrough. WAYA https://lnkd.in/ehqShBiz #lifesciences

2025 is starting strong for STL! St. Louis startups are making waves with Geneoscopy raising $105M for its at-home colorectal cancer test, Arch Grants awarding $300K to grow local businesses, and BioSTL's NEURO360 vying for a $160M grant to advance the region's neuroscience industry. #STLMade St. Louis-based cancer test firm closes $105M funding round #stlmade startup @GeneoscopyCo has raised $105M in Series C funding to support the commercial launch of its ColoSense at-home screening test for colorectal cancer. More: https://lnkd.in/gXjVBR5n Bathroom ads, a sales system and medical study tool get $300K in Arch Grants funding Three #stlmade startups have been awarded a total of $300K in Growth Grants from @ArchGrants to help grow their businesses. The Growth Grants program provides follow-up resources to Arch Grant companies that have created jobs and expanded operations in St. Louis. More: https://lnkd.in/gG-N4kE3 BioSTL to 'supercharge' St. Louis neuroscience industry Startup accelerator @BioSTL’s NEURO360 coalition was recently named a finalist in @NSF’s Regional Innovation Engines Program. If chosen, the organization would use the $160M in grant funding to supercharge the region’s neuroscience industry. More: https://lnkd.in/g58txRaM